Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (1854)	9/19/2005 12:37:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 1870

Genta: Data From Phase 3 Trial Of Genasense Confirm Extended Durability Of Remission And Benefit In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia Genta Up 37% On New Data On Anti-Cancer Drug DOW JONES NEWSWIRES September 19, 2005 11:58 a.m. By Peter Loftus Of DOW JONES NEWSWIRES Genta Inc. (GNTA) shares jumped 38% Monday after the pharmaceutical company said leukemia patients who took its anti-cancer drug in a trial had longer remissions and lower risk of relapses. The Berkeley Heights, N.J., company had previously said its Genasense drug, in combination with chemotherapy, increased "major response" in patients with relapsed or refractory chronic lymphocytic leukemia, or CLL. Genta said Monday a Phase 3 trial of Genasense plus chemotherapy showed "significantly longer remission duration and significantly lower risk of relapse." Genta said it presented the data at medical conferences. Genta has initiated a new-drug application with the Food and Drug Administration, seeking accelerated approval of Genasense in patients with CLL. The company requested a meeting with the FDA to discuss plans for a confirmatory post-approval study. Genta shares rose 49 cents to $1.77, on volume of 28.7 million shares, well above the daily average of 1.5 million. Earlier the stock rose to $1.98 for a gain of more than 50%.